SEP
KRYS icon

Signature Equity Partners’s Krystal Biotech KRYS Stock Holding History

Signature Equity Partners’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$743 Hold
2
– – ﹤0.01% 1371
2026
Q1 		$517 Hold
2
– – ﹤0.01% 1369
2025
Q4 		$493 Buy
+2
New +$421 ﹤0.01% 1527

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Signature Equity Partners's KRYS Position: Q2 2026 in Review

Signature Equity Partners held its Krystal Biotech (KRYS) position steady in Q2 2026 at 2 shares worth $743. The position accounts for ﹤0.01% of the portfolio, ranked #1371.

Signature Equity Partners first reported a position in KRYS in Q4 2025 and has held it in 3 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Signature Equity Partners held 2 shares of Krystal Biotech worth $743 as of Q2 2026.
  • Signature Equity Partners left its Krystal Biotech share count unchanged in Q2 2026.
  • Krystal Biotech made up ﹤0.01% of Signature Equity Partners's portfolio in Q2 2026, its #1371 holding.
  • Signature Equity Partners first reported a position in Krystal Biotech in Q4 2025 and has held it in 3 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.